Avid Bioservices Inc (CDMO)

[cheynew]

From The Motley Fool:

Moving to the fast lane
On Monday, clinical-stage biopharmaceutical company Peregrine Pharmaceuticals (NASDAQ: PPHM ) put its blinker on and shifted over to the fast lane after it announced that the FDA had granted its second-line immunotherapy treatment for non-small-cell lung cancer, bavituximab, the fast-track designation. This designation allows Peregrine more frequent interaction between it and the FDA and could lead to an expedited review of its cancer drug. In addition, Peregrine also announced that it had begun initiating its phase 3 trial known as Sunrise for bavituximab. With Peregrine's mid-stage study marred by an outside clinical lab, investors will be looking for consistently impressive results in phase 3 trials if Peregrine is going to regain its highs achieved in 2012.


http://www.fool.com/investing/general/2014/01/11/this-week-in-biotech-the-fda-nice-and-doj-weigh-in.aspx